Cell and Gene Therapy CDMO Market Size, Share and Growth Outlook, 2026

Cell and Gene Therapy CDMO Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cell and Gene Therapy CDMO Market size is forecast to increase from $6.23 Billion in 2026 to $31.8 Billion in 2034 at a CAGR of 22.6% between 2026 and 2034.

The Cell and Gene Therapy CDMO market report provides detailed analysis and outlook of Cell and Gene Therapy CDMO segments including By Therapy (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy ), By Service Type (Process Development and Analytical Testing, Clinical-Stage Development and Manufacturing, Commercial-Scale GMP Manufacturing, Fill-Finish and Packaging Services), By Indication (Oncology, Rare Diseases and Genetic Disorders, Neurological and Central Nervous System Disorders, Infectious and Cardiovascular Diseases), By Client (Biopharmaceutical and Pharmaceutical Corporations, Biotech Startups and Universities) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cell and Gene Therapy CDMO Industry Overview

Manufacturing Scale-Up Driving Growth in Advanced Therapy Production

The cell and gene therapy contract development and manufacturing organization (CDMO) industry is experiencing substantial expansion as biopharmaceutical companies increasingly outsource complex manufacturing operations for cell therapies, gene therapies, viral vectors, and gene-edited products. The rapid growth of advanced therapy pipelines, coupled with stringent regulatory requirements and specialized production needs, is driving demand for large-scale, cGMP-compliant manufacturing infrastructure. CDMOs are investing heavily in automation, modular facilities, single-use technologies, and commercial-scale production capabilities to support clients from early-stage development through global commercialization.

Strategic Manufacturing Partnerships Supporting Commercial Cell Therapies

Long-term manufacturing collaborations are becoming a defining feature of the cell and gene therapy CDMO landscape. Lonza Group AG finalized a multi-product strategic manufacturing agreement with Vertex Pharmaceuticals focused on scaling commercial production for Vertex’s portfolio of gene-edited cell therapies. Under the collaboration, Lonza will leverage its dedicated cGMP-compliant cell and gene therapy facility in Geleen, Netherlands, to provide large-scale drug product manufacturing alongside automated fill-finish operations. The agreement highlights the increasing reliance of therapy developers on specialized CDMO partners capable of supporting commercial-scale production of highly complex advanced therapies while ensuring quality, consistency, and regulatory compliance.

Expansion of Viral Vector Manufacturing Capacity Accelerating Industry Development

The growing demand for viral vectors continues to drive major infrastructure investments across the CDMO sector. Catalent advanced its biologics manufacturing capabilities through the completion of a $180 million expansion project at its Harmans, Maryland gene therapy campus. The investment added multiple commercial-scale suspension bioreactor production lines and advanced downstream purification suites, significantly expanding the company’s capacity for large-scale viral vector manufacturing. As viral vectors remain essential delivery mechanisms for many gene therapy products, increased production capabilities are helping address industry-wide capacity constraints and support the growing number of clinical and commercial gene therapy programs.

Flexible Manufacturing Facilities Enhancing Production Agility

Modern cell and gene therapy manufacturing increasingly requires adaptable production environments capable of supporting diverse therapeutic modalities. Fujifilm Diosynth Biotechnologies formally opened a new automated manufacturing facility in Thousand Oaks, California, designed to accommodate viral vectors, plasmid DNA, and cell-based therapies. The site incorporates modular cleanroom architecture and standardized disposable single-use technologies that enable rapid process transitions and scalable production. By supporting programs from early clinical development through commercial distribution, the facility reflects the industry's shift toward flexible manufacturing platforms capable of addressing evolving client requirements while improving operational efficiency and reducing production timelines.

Cell and Gene Therapy CDMO Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cell and Gene Therapy CDMO market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc. , WuXi Advanced Therapies , MilliporeSigma , FUJIFILM Diosynth Biotechnologies, Charles River Laboratories International, Inc., Siegfried Holding AG, AGC Biologics, Minaris Advanced Therapies. The Cell and Gene Therapy CDMO market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cell and Gene Therapy CDMO industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cell and Gene Therapy CDMO Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cell and Gene Therapy CDMO companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cell and Gene Therapy CDMO markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cell and Gene Therapy CDMO Market Competitive Benchmarking and Company Analysis

Leading companies in Cell and Gene Therapy CDMO industry include- Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc. , WuXi Advanced Therapies , MilliporeSigma , FUJIFILM Diosynth Biotechnologies, Charles River Laboratories International, Inc., Siegfried Holding AG, AGC Biologics, Minaris Advanced Therapies. The Cell and Gene Therapy CDMO market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cell and Gene Therapy CDMO Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cell and Gene Therapy CDMO market remains one of the strongest-performing segments in the country.
The US Cell and Gene Therapy CDMO Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cell and Gene Therapy CDMO market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cell and Gene Therapy CDMO industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cell and Gene Therapy CDMO markets

Canada's strong Cell and Gene Therapy CDMO sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cell and Gene Therapy CDMO market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cell and Gene Therapy CDMO Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cell and Gene Therapy CDMO market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cell and Gene Therapy CDMO population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cell and Gene Therapy CDMO industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cell and Gene Therapy CDMO market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cell and Gene Therapy CDMO sales through 2034

France Cell and Gene Therapy CDMO companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cell and Gene Therapy CDMO Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cell and Gene Therapy CDMO distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cell and Gene Therapy CDMO Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cell and Gene Therapy CDMO market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cell and Gene Therapy CDMO industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cell and Gene Therapy CDMO industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cell and Gene Therapy CDMO Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cell and Gene Therapy CDMO market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cell and Gene Therapy CDMO market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cell and Gene Therapy CDMO Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cell and Gene Therapy CDMO Market Segmentation

By Therapy
Cell Therapy
Gene Therapy
Gene-Modified Cell Therapy
By Service Type
Process Development and Analytical Testing
Clinical-Stage Development and Manufacturing
Commercial-Scale GMP Manufacturing
Fill-Finish and Packaging Services
By Indication
Oncology
Rare Diseases and Genetic Disorders
Neurological and Central Nervous System Disorders
Infectious and Cardiovascular Diseases
By Client
Biopharmaceutical and Pharmaceutical Corporations
Biotech Startups and Universities

Top Companies in Cell and Gene Therapy CDMO Industry

Lonza Group AG
Catalent, Inc.
Thermo Fisher Scientific Inc.
WuXi Advanced Therapies
MilliporeSigma
FUJIFILM Diosynth Biotechnologies
Charles River Laboratories International, Inc.
Siegfried Holding AG
AGC Biologics
Minaris Advanced Therapies

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025